Replies to post #22924 on DNAprint Genomics (DNAG)

[Don'tDrinkTheKoolAid]

Everyone knew this was coming big deal no effect on dnap. All the big drug companies could have acted or already did act by joinig with other genomics co's. Say it ain't so. LOL

[ifida]

Frog....brings back memories of this PR...

Sarasota Herald Tribune
Article published Sep 24, 2002
DNAPrint to launch a new genetic test


SARASOTA -- DNAPrint Genomics Inc. plans to market a genetic test that it says can tell which medication is best for people at risk for developing cardiovascular disease.

The research and development company on Monday said it will pitch the test, called "Statnome," primarily to health maintenance organizations and other insurers.

"They are the ones who will save by using these tests," said Tony Frudakis, DNAPrint's chief executive officer. "They are the ones paying the expense of one-size-fits-all drug prescriptions."

Statnome looks at genetic differences in people who take statins, a class of prescription drugs used to treat lipoprotein disorders and reduce the risk of cardiovascular disease. There are perhaps a dozen statins available, but DNAPrint studied atorvastatin and simvastatin, two market leaders.

Patients who reacted well to standard doses of atorvastatin, which sells under the brand name Lipitor, had different genetic variations from those who responded positively to standard doses of simvastatin, sold under the brand name Zocor.

Statnome was developed over two years after studying the drug responses of 575 patients. The test uses seven measurements, including how well the medications worked and whether they were likely to cause liver stress or muscle pain.

DNAPrint also plans to begin offering Ovanome, a similar test for ovarian cancer patients.

Frudakis said Statnome could improve the safety and effectiveness of atorvastatin and simvastatin, with combined annual sales of $12 billion, Frudakis said.

It could also reduce negative reactions to statins and help change the trial-and-error method of prescribing. Drug maker Bayer pulled Baycol, a type of a statin, from the market after deaths were linked to that medication.

Frudakis estimates 30 million Americans are at risk of developing a lipoprotein condition that can lead to cardiovascular disease. He said he knows of at least one Statnome-like test that is being developed.

DNAPrint's shares, which trade over the counter, were selling for 2.8 cents per share, unchanged, at the close of regular trading Monday.



IFIDA

[bag8ger]

froggy,

Do I detect a trembling of excitement running down your arms and fingers as you typed that post?

It must give you great satisfaction to infer that DNAP has been edged out, that the large pharmas will remain in power, and that their noble commitment to personalized medicine will save mankind.

A veritable tsunami of warm hearted dedication launched by an FDA they have had in their pockets and coerced from the getgo.

I hope you're right. I hope all of large pharma will now turn to personalized medicine.

It will be better for its customers by far.

I hope that DNAP will stay at the table long enough to be thrown the scraps.

Gives me the shivers just to contemplate it.